These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

860 related items for PubMed ID: 26585048

  • 1. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data.
    Guhra M, Thomas C, Boedeker S, Kreisel S, Driessen M, Beblo T, Ohrmann P, Toepper M.
    Exp Gerontol; 2016 Jan; 73():107-13. PubMed ID: 26585048
    [Abstract] [Full Text] [Related]

  • 2. Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.
    Reijs BLR, Ramakers IHGB, Köhler S, Teunissen CE, Koel-Simmelink M, Nathan PJ, Tsolaki M, Wahlund LO, Waldemar G, Hausner L, Vandenberghe R, Johannsen P, Blackwell A, Vanderstichele H, Verhey F, Visser PJ.
    J Alzheimers Dis; 2017 Jan; 60(3):1119-1128. PubMed ID: 28984585
    [Abstract] [Full Text] [Related]

  • 3. Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition.
    Reijs BLR, Ramakers IHGB, Elias-Sonnenschein L, Teunissen CE, Koel-Simmelink M, Tsolaki M, Wahlund LO, Waldemar G, Hausner L, Johannsen P, Vanderstichele H, Verhey F, Devanand DP, Visser PJ.
    J Alzheimers Dis; 2017 Jan; 60(3):1025-1034. PubMed ID: 28984603
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
    Alves G, Brønnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E.
    J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
    [Abstract] [Full Text] [Related]

  • 6. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.
    J Alzheimers Dis; 2015 Oct; 44(2):525-39. PubMed ID: 25391385
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K.
    JAMA; 2009 Jul 22; 302(4):385-93. PubMed ID: 19622817
    [Abstract] [Full Text] [Related]

  • 9. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O, Cretin B, Lavaux T, Philippi N, Jung B, Hezard S, Heitz C, Demuynck C, Gabel A, Martin-Hunyadi C, Blanc F.
    J Alzheimers Dis; 2016 Jul 22; 51(4):1069-83. PubMed ID: 26923009
    [Abstract] [Full Text] [Related]

  • 10. Progranulin and Amyloid-β Levels: Relationship to Neuropsychology in Frontotemporal and Alzheimer's Disease.
    Körtvélyessy P, Gukasjan A, Sweeney-Reed CM, Heinze HJ, Thurner L, Bittner DM.
    J Alzheimers Dis; 2015 Jul 22; 46(2):375-80. PubMed ID: 25777512
    [Abstract] [Full Text] [Related]

  • 11. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S, Santangelo R, Bernasconi MP, Cecchetti G, Fiorino A, Pinto P, Passerini G, Falautano M, Comi G, Magnani G.
    J Alzheimers Dis; 2016 Oct 18; 54(4):1495-1508. PubMed ID: 27589522
    [Abstract] [Full Text] [Related]

  • 12. Preclinical AD predicts decline in memory and executive functions in subjective complaints.
    van Harten AC, Smits LL, Teunissen CE, Visser PJ, Koene T, Blankenstein MA, Scheltens P, van der Flier WM.
    Neurology; 2013 Oct 15; 81(16):1409-16. PubMed ID: 24049134
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
    Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K.
    Arch Neurol; 2001 Mar 15; 58(3):373-9. PubMed ID: 11255440
    [Abstract] [Full Text] [Related]

  • 14. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L.
    Lancet Neurol; 2006 Mar 15; 5(3):228-34. PubMed ID: 16488378
    [Abstract] [Full Text] [Related]

  • 15. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
    Mulugeta E, Londos E, Ballard C, Alves G, Zetterberg H, Blennow K, Skogseth R, Minthon L, Aarsland D.
    J Neurol Neurosurg Psychiatry; 2011 Feb 15; 82(2):160-4. PubMed ID: 21047883
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Dual-Task Performance and Neurodegeneration: Correlations Between Timed Up-and-Go Dual-Task Test Outcomes and Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
    Åhman HB, Giedraitis V, Cedervall Y, Lennhed B, Berglund L, McKee K, Kilander L, Rosendahl E, Ingelsson M, Åberg AC.
    J Alzheimers Dis; 2019 Feb 15; 71(s1):S75-S83. PubMed ID: 31104024
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.